Aeglea Bio Shares Owned By Institutions vs. Revenue
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
For Aeglea Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aeglea Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aeglea Bio Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aeglea Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aeglea Bio Therapeutics over time as well as its relative position and ranking within its peers.
Aeglea |
Aeglea Bio Therapeutics Revenue vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aeglea Bio's current stock value. Our valuation model uses many indicators to compare Aeglea Bio value to that of its competitors to determine the firm's financial worth. Aeglea Bio Therapeutics is rated third in shares owned by institutions category among its peers. It also is rated third in revenue category among its peers totaling about 23,863 of Revenue per Shares Owned By Institutions. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aeglea Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Aeglea Revenue vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Aeglea Bio |
| = | 97.60 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Aeglea Bio |
| = | 2.33 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Aeglea Revenue vs Competition
Aeglea Bio Therapeutics is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 129.54 Million. Aeglea Bio claims roughly 2.33 Million in revenue contributing just under 2% to equities under Health Care industry.
Aeglea Bio Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aeglea Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aeglea Bio will eventually generate negative long term returns. The profitability progress is the general direction of Aeglea Bio's change in net profit over the period of time. It can combine multiple indicators of Aeglea Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Aeglea Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aeglea Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aeglea Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aeglea Bio's important profitability drivers and their relationship over time.
Use Aeglea Bio in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aeglea Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aeglea Bio will appreciate offsetting losses from the drop in the long position's value.Aeglea Bio Pair Trading
Aeglea Bio Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Aeglea Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aeglea Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aeglea Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aeglea Bio Therapeutics to buy it.
The correlation of Aeglea Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aeglea Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aeglea Bio Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aeglea Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aeglea Bio position
In addition to having Aeglea Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |